AzTrials
AzTrials

COVID-19NCT06795880

"Artificial Intelligence-Based Data Analysis Results and Mortality Prediction in Covid-19 Patients in Intensive Care"

An observational study of COVID-19, run by Kocaeli City Hospital at 1 site in Turkey (Türkiye).

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

An artificial intelligence-based analysis will be performed using retrospective data of patients treated in adult intensive care units due to COVID-19. The dataset will include various parameters such as demographic information, laboratory results, vital signs, and clinical history. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
COVID-19
How many people
400 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Apr 2020to 5 Mar 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: An artificial intelligence-based analysis will be performed using retrospective data of patients treated in adult intensive care due to COVID-19.The dataset will include various parameters such as demographic information, laboratory results, vital signs, and clinical history.Among the ML models, logistic regression, support vector machines (SVM), decision trees, and deep learning techniques (e.g., artificial neural networks) will be used. The performance of the models will be compared with traditional scoring systems.

Who may be able to join

  • All patients diagnosed with Covid-19 in the anesthesia and reanimation adult intensive care unit

Who cannot join

  • Participants who do not meet the inclusion criteria stated above will be excluded from the study.

Trial locations and contacts

1 site in 1 country.

Turkey (Türkiye)1 site
  • Kocaeli City Hospital

    İzmit, Kocaeli, 41060

Other trials in Turkey (Türkiye)

About this study

An artificial intelligence-based analysis will be performed using retrospective data of patients treated in adult intensive care units due to COVID-19. The dataset will include various parameters such as demographic information, laboratory results, vital signs, and clinical history. Among the machine learning models, logistic regression, support vector machines (SVM), decision trees, and deep learning techniques (e.g., artificial neural networks) will be utilized. The performance of these models will be compared with traditional scoring systems.

As a result of the analysis, it is anticipated that AI-based models will provide higher accuracy and reliability in mortality prediction. In particular, it is expected that deep learning-based models will better capture complex relationships and predict the outcomes of critically ill patients with greater precision. AI-supported data analysis results have the potential to guide diagnosis and treatment strategies in high-risk intensive care patients and can contribute to mortality prediction. AI-based approaches in intensive care are likely to offer significant advantages in the management of critical diseases such as COVID-19. These methods have the potential to improve clinical decision-making processes by providing healthcare professionals with more precise and timely information.

Read the detailed description

In this research, patient information obtained through retrospective archive scanning in high-risk patients followed up in the Anesthesia Intensive Care Unit with a diagnosis of COVID-19 will be recorded, and data analysis will be performed using artificial intelligence-based machine learning methods. The applicability of the obtained results in predicting the morbidity and mortality of patients, as well as the accuracy and reliability of these data, will be discussed.

The COVID-19 pandemic has strained healthcare systems worldwide, creating significant challenges in the management of critically ill patients, particularly in adult anesthesia intensive care units. During this process, accurately predicting the morbidity and mortality risks of patients is essential for the effective use of healthcare resources and the improvement of patient care. Traditional mortality prediction methods are generally based on clinical scoring systems and manual analysis of patient data. However, the accuracy and reliability of these methods remain limited. Artificial intelligence (AI) and machine learning (ML) techniques offer promising results in this field due to their capacity to analyze large datasets and detect complex patterns.

AI applications are used in various ways to evaluate and improve the effectiveness of intensive care treatments in COVID-19 patients. In this context, AI can be utilized in critically ill intensive care patients. Based on current information, AI can be applied to tasks such as data collection, data analysis and modeling, prognostic model development, result visualization, natural language processing (NLP), and decision support systems.

In data collection, AI algorithms can be employed to gather large and diverse datasets from hospitals quickly and accurately. This minimizes data inconsistencies and omissions, enhancing the accuracy of the study. Machine learning algorithms can analyze various variables such as patients' demographic data, disease severity, treatment protocols, and outcomes to determine the factors with the greatest impact on mortality. Algorithms such as regression models, decision trees, and random forests are commonly used for this purpose.

AI-based prognostic models can be developed using patient data to predict the most effective treatment for individual patients. These models can support optimization of treatment decisions by predicting patient responses to treatment. Furthermore, AI-powered visualization tools, such as interactive graphs and heat maps, can assist in understanding and interpreting study findings by highlighting relationships between treatment responses and mortality rates.

Natural Language Processing (NLP) can analyze unstructured data, including patient notes and medical records, to provide additional insights into treatment efficacy and side effects. This capability expands the scope of retrospective studies and enhances the accuracy of the results. AI-based decision support systems can also offer recommendations to physicians on suitable treatments for specific patient profiles, integrating clinical guidelines and the latest scientific literature.

AI-based approaches offer significant advantages in the management of critical illnesses such as COVID-19, especially in intensive care units. These methods have the potential to improve clinical decision-making by providing healthcare professionals with more precise and timely information. Additionally, AI models can quickly adapt to emerging patterns by updating themselves with new data. However, ethical and technical challenges must be addressed carefully to ensure the widespread adoption of these approaches in clinical practice.

This study aims to generate promising and informative results through data analysis performed with artificial intelligence and machine learning on the records of COVID-19 patients in intensive care. The effectiveness of AI-based machine learning methods in predicting the mortality of critically ill patients treated in intensive care due to COVID-19 will be investigated. AI-based approaches provide higher accuracy and reliability compared to traditional methods and can contribute to improved outcomes in healthcare systems. These findings may highlight the potential of artificial intelligence applications in managing future pandemics such as COVID-19 and other critical illnesses.

Conditions
COVID-19
Keywords
intensive care, machine learning, mortality
Medical subject headings
COVID-19

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mortality prediction in covid-19 patients in intensive care using artificial intelligence models

    Mortality prediction in covid-19 patients in intensive care using artificial intelligence models, analysis of patient data with artificial intelligence models.

    Measured: "through study completion, an average of 4 year"

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Jan 2025
  2. Study start1 Apr 2020
  3. Primary completion1 Apr 2024
  4. Study completion5 Mar 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Retrospective
Enrolment
400 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06795880
Sponsor's protocol ID
2024-74
Status last verified
Aug 2026
First submitted
24 Jan 2025
Last updated
11 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Chee ML, Ong MEH, Siddiqui FJ, Zhang Z, Lim SL, Ho AFW, Liu N. Artificial Intelligence Applications for COVID-19 in Intensive Care and Emergency Settings: A Systematic Review. Int J Environ Res Public Health. 2021 Apr 29;18(9):4749. doi: 10.3390/ijerph18094749.

    PubMed 33947006

Questions about this trial

What is this clinical trial studying?

An observational study of COVID-19, run by Kocaeli City Hospital at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 11 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mortality prediction in covid-19 patients in intensive care using artificial intelligence models (time frame: "through study completion, an average of 4 year"). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06795880, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Aug 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in